Amyris, Inc. (NASDAQ:AMRS) Given Average Rating of “Hold” by Analysts

Shares of Amyris, Inc. (NASDAQ:AMRSGet Rating) have received an average rating of “Hold” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $22.00.

A number of equities research analysts have recently weighed in on the stock. StockNews.com assumed coverage on shares of Amyris in a research report on Thursday, March 31st. They issued a “sell” rating for the company. Zacks Investment Research downgraded shares of Amyris from a “hold” rating to a “sell” rating in a research report on Monday.

Shares of AMRS stock opened at $2.26 on Thursday. The firm has a 50 day moving average price of $3.86 and a two-hundred day moving average price of $5.19. The company has a quick ratio of 1.46, a current ratio of 1.77 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $722.55 million, a PE ratio of -1.84 and a beta of 1.63. Amyris has a 12-month low of $1.47 and a 12-month high of $17.42.

Amyris (NASDAQ:AMRSGet Rating) last issued its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.07). The business had revenue of $57.71 million for the quarter, compared to analysts’ expectations of $65.45 million. The firm’s revenue was down 67.4% on a year-over-year basis. During the same period in the previous year, the business earned ($1.08) EPS. As a group, research analysts expect that Amyris will post -0.8 EPS for the current year.

Large investors have recently made changes to their positions in the stock. Farallon Capital Management LLC grew its stake in shares of Amyris by 55.9% during the first quarter. Farallon Capital Management LLC now owns 16,931,427 shares of the biotechnology company’s stock worth $73,821,000 after buying an additional 6,071,616 shares during the last quarter. Millennium Management LLC grew its stake in shares of Amyris by 690.3% during the fourth quarter. Millennium Management LLC now owns 3,104,134 shares of the biotechnology company’s stock worth $16,793,000 after buying an additional 2,711,364 shares during the last quarter. State of Michigan Retirement System grew its stake in shares of Amyris by 92.2% during the first quarter. State of Michigan Retirement System now owns 4,815,000 shares of the biotechnology company’s stock worth $20,993,000 after buying an additional 2,310,000 shares during the last quarter. Edmond DE Rothschild Holding S.A. grew its stake in shares of Amyris by 83.9% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 4,563,800 shares of the biotechnology company’s stock worth $19,898,000 after buying an additional 2,081,500 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale grew its stake in shares of Amyris by 2,531.6% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 2,000,000 shares of the biotechnology company’s stock worth $10,391,000 after buying an additional 1,924,000 shares during the last quarter. 49.43% of the stock is currently owned by institutional investors and hedge funds.

About Amyris (Get Rating)

Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.

Recommended Stories

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.